Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
作者信息
Rolfes Leoni, Meuth Sven G
机构信息
Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany.
出版信息
Mult Scler. 2022 Apr;28(5):691-693. doi: 10.1177/13524585211055593. Epub 2021 Dec 21.
Abstract
摘要
相似文献
1
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-"Yes".
Mult Scler. 2022 Apr;28(5):691-693. doi: 10.1177/13524585211055593. Epub 2021 Dec 21.
2
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing: NO.
Mult Scler. 2022 Apr;28(5):693-695. doi: 10.1177/13524585211064441. Epub 2022 Jan 7.
3
Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing-Commentary.
Mult Scler. 2022 Apr;28(5):695-696. doi: 10.1177/13524585211067708.
4
Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
CNS Drugs. 2021 Sep;35(9):985-997. doi: 10.1007/s40263-021-00843-8. Epub 2021 Aug 9.
5
Proinflammatory CD20 T Cells are Differentially Affected by Multiple Sclerosis Therapeutics.
Ann Neurol. 2021 Nov;90(5):834-839. doi: 10.1002/ana.26216. Epub 2021 Oct 2.
6
Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis.
Brain. 2019 Jan 1;142(1):120-132. doi: 10.1093/brain/awy301.
7
Derisking CD20-therapies for long-term use.
Mult Scler Relat Disord. 2022 Jan;57:103418. doi: 10.1016/j.msard.2021.103418. Epub 2021 Nov 22.
8
Rituximab in patients with pediatric multiple sclerosis and other demyelinating disorders of the CNS: Practical considerations.
Mult Scler. 2021 Oct;27(12):1814-1822. doi: 10.1177/1352458520932798. Epub 2020 Jun 19.
9
Learning multiple sclerosis immunopathogenesis from anti-CD20 therapy.
Proc Natl Acad Sci U S A. 2023 Feb 7;120(6):e2221544120. doi: 10.1073/pnas.2221544120. Epub 2023 Jan 31.
10
Extended dosing of monoclonal antibodies in multiple sclerosis.
Mult Scler. 2022 Nov;28(13):2001-2009. doi: 10.1177/13524585211065711. Epub 2021 Dec 24.
引用本文的文献
1
Profile of Ofatumumab in the Treatment of Multiple Sclerosis: Design, Development and Place in Therapy.
Drug Des Devel Ther. 2024 Dec 12;18:5985-5996. doi: 10.2147/DDDT.S315174. eCollection 2024.
2
De-escalation of anti-CD20 monoclonal antibodies to low-moderate efficacy disease-modifying treatments (DMTs) in patients with relapse-remitting multiple sclerosis: An initial Iranian experience.
Caspian J Intern Med. 2024 Oct 19;16(1):126-131. doi: 10.22088/cjim.16.1.126. eCollection 2025 Winter.
3
Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder.
Sci Rep. 2024 Feb 12;14(1):3503. doi: 10.1038/s41598-024-53838-y.
4
Should anti-CD20 be used as an immune reconstitution therapy?
Mult Scler. 2023 Feb;29(2):308-310. doi: 10.1177/13524585221109386. Epub 2022 Jul 13.
本文引用的文献
1
Association of Disease-Modifying Treatment and Anti-CD20 Infusion Timing With Humoral Response to 2 SARS-CoV-2 Vaccines in Patients With Multiple Sclerosis.
JAMA Neurol. 2021 Dec 1;78(12):1529-1531. doi: 10.1001/jamaneurol.2021.3609.
2
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.
Neurol Neuroimmunol Neuroinflamm. 2021 Jul 14;8(5). doi: 10.1212/NXI.0000000000001035. Print 2021 Sep.
3
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness.
Mult Scler Relat Disord. 2021 Feb;48:102704. doi: 10.1016/j.msard.2020.102704. Epub 2020 Dec 21.
4
Tailoring B cell depletion therapy in MS according to memory B cell monitoring.
Neurol Neuroimmunol Neuroinflamm. 2020 Aug 4;7(5). doi: 10.1212/NXI.0000000000000845. Print 2020 Sep.
5
The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.
Mult Scler Relat Disord. 2020 Sep;44:102279. doi: 10.1016/j.msard.2020.102279. Epub 2020 Jun 8.
6
Extending rituximab dosing intervals in patients with MS during the COVID-19 pandemic and beyond?
Neurol Neuroimmunol Neuroinflamm. 2020 Jun 25;7(5). doi: 10.1212/NXI.0000000000000825. Print 2020 Sep.
7
Interrupting rituximab treatment in relapsing-remitting multiple sclerosis; no evidence of rebound disease activity.
Mult Scler Relat Disord. 2020 Jan;37:101468. doi: 10.1016/j.msard.2019.101468. Epub 2019 Oct 24.
8
Peripheral CD19 B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders.
J Neurol. 2019 Jan;266(1):57-67. doi: 10.1007/s00415-018-9092-4. Epub 2018 Oct 30.
9
Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial.
Ann Neurol. 2008 Mar;63(3):395-400. doi: 10.1002/ana.21363.
Zotero 插件